Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.200 +0.110 (+3.56%) Streaming Delayed Price Updated: 12:22 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 128,442 Open 3.100 Bid (Size) 3.180 (4) Ask (Size) 3.220 (20) Prev. Close 3.090 Today's Range 3.050 - 3.370 52wk Range 0.7598 - 6.850 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing July 22, 2024 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing July 22, 2024 Via Investor Brand Network Performance YTD +148.06% +148.06% 1 Month +23.55% +23.55% 3 Month +46.12% +46.12% 6 Month +119.18% +119.18% 1 Year +313.86% +313.86% More News Read More CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study July 17, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study July 17, 2024 Via ACCESSWIRE Lexaria Preparing For Strategic Growth July 16, 2024 Via ACCESSWIRE Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study July 09, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study July 17, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide July 17, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth July 16, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy July 08, 2024 Via ACCESSWIRE Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study June 18, 2024 Via ACCESSWIRE Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study July 15, 2024 Via Investor Brand Network LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024 July 12, 2024 Via InvestorPlace CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study July 09, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study July 09, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy July 08, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players June 27, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July June 24, 2024 Via Investor Brand Network 7 A-Rated Penny Stocks to Beat June Gloom June 24, 2024 Via InvestorPlace HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study June 18, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study June 17, 2024 Via Investor Brand Network 7 A-Rated Biotech Stocks Worth Betting on in June June 14, 2024 Via InvestorPlace Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide June 06, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study June 05, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study June 05, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
